As we have previously reported, the United States Judicial Panel on Multidistrict Litigation (JPML) granted multidistrict litigation (MDL) treatment to the incretin mimetic litigation, meaning that all federal lawsuits filed across the United States are now centralized in one judicial district. The incretin mimetic litigation, which includes the medications Byetta, Januvia/Janumet and Victoza, was centralized in the Southern District of California. This consolidation streamlines the pretrial discovery process, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.

The Honorable Anthony J. Battaglia is presiding over the litigation in the Southern District of California. Judge Battaglia recently set deadlines for the parties regarding the composition of the Master Consolidated Answer. The court tentatively set December 31, 2013, as the deadline for when Defendants must file the Master Consolidated Answer.

If you or a loved one has suffered from pancreatic cancer after taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any potential claims.